Madhav Thambisetty, MD, PhD, MBRF Trustee and Vice Chair, senior investigator at the National Institute on Aging and adjunct professor of neurology at the Johns Hopkins University School of Medicine, recently addressed the important topic of “Targeting Pathology in Neurogenerative Disease” at the Plenary Session of the 2023 Annual Meeting of the American Academy of Neurology. The topic is especially timely given the many treatments recently reported to be beneficial for neurodegenerative disease, but accompanied by serious side effects and sometimes death without clinically significant improvement in the disease. In his talk, Dr. Thambisetty also presented the challenges and advancements in the field of neurodegenerative diseases, and the need for greater transparency in clinical trial results.
Thambisetty sat down with NeurologyLive® in an interview at the AAN Annual Meeting to discuss the most promising approaches that currently target the pathologies in neurodegenerative diseases as well as how those differ from previous treatments. He also talked about how researchers balance the need for early intervention in neurodegenerative disease with the potential risks of adverse events with treatments. In addition, Thambisetty shared his insight into the role of interdisciplinary collaborations, such as in the different fields of science and medicine, in developing effective strategies for targeting pathology in neurodegenerative disease.
“I think this is a very exciting time for us in neurodegenerative diseases. As far as Alzheimer disease [AD] is concerned, it looks as if we might for the first time in decades be able to target some of the fundamental pathological changes in the brain in patients with AD. That in itself, is a scientific milestone, it’s a landmark and there’s a lot of hope around these treatments.”Madhav Thambisetty, MD, PhD, MBRF Trustee and Vice Chair